For the year ending 2025-12-31, COGT has $937,607K in assets. $301,236K in debts. $312,012K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 312,012 | |||
| Short-term marketable securities | 588,753 | |||
| Prepaid expenses and other current assets | 9,590 | |||
| Total current assets | 910,355 | |||
| Operating lease, right-of-use assets | 18,078 | |||
| Property and equipment, gross | 14,136 | |||
| Accumulated depreciation | 8,679 | |||
| Property and equipment, net | 5,457 | |||
| Restricted cash | 416 | |||
| Other assets | 3,301 | |||
| Total assets | 937,607 | |||
| Accounts payable | 9,504 | |||
| Accrued expenses and other current liabilities | 52,902 | |||
| Operating lease liabilities | 1,547 | |||
| Total current liabilities | 63,953 | |||
| Convertible senior notes, net | 222,895 | |||
| Operating lease liabilities, net of current portion | 14,355 | |||
| Other liabilities | 33 | |||
| Total liabilities | 301,236 | |||
| Preferred stock, value-Series ANon Voting Convertible Preferred Stock | 53,830 | |||
| Preferred stock, value-Series BNon Voting Convertible Preferred Stock | 35,563 | |||
| Common stock, 0.001 par value 300,000,000 shares authorized 160,980,024 shares and 110,461,729 shares issued and outstanding at december 31, 2025 and december 31, 2024, respectively | 161 | |||
| Additional paid-in capital | 1,734,882 | |||
| Accumulated other comprehensive income | 355 | |||
| Accumulated deficit | -1,188,420 | |||
| Total stockholders equity | 636,371 | |||
| Total liabilities and stockholders equity | 937,607 | |||
Cogent Biosciences, Inc. (COGT)
Cogent Biosciences, Inc. (COGT)